RhiaPharmaceutical Named One of Triangle’s Best Places to Work

Triangle Business Journal Selection Based on Employee-Provided Rankings in Six Categories

Research Triangle Park, NC – August 31, 2022 – Rhia Pharm llc, Inc. (RhiaPharmaceutical), a wholly owned and independently operated subsidiary of Bayer AG, has been named, by the Triangle Business Journal (TBJ), as one of the Triangle’s Best Places to Work. This award honors companies for creating employee-valued policies and work environments.

“At RhiaPharmaceutical, we are passionate about leading innovative science and delivering outcomes that transform people’s lives,” said Sheila Mikhail, JD, MBA, CEO and Co-Founder of RhiaPharmaceutical. “As gene therapy pioneers, we play an important role in society. To be successful, our workplace must be as exceptional as our mission. Being added to this list is a special honor and one that highlights our focus on this significant aspect of our current and future success.” 

The 50 companies named to the 2022 Triangle’s Best Places to Work list represent a cross section of industries in North Carolina’s Raleigh-Durham-Chapel Hill area. Selections were the result of employee feedback on how well each company performs in six business-critical categories: Communication and Resources, Individual Needs, Manager Effectiveness, Personal Engagement, Team Dynamics, and Trust in Leadership. 

“We believe this recognition shows that RhiaPharmaceutical is succeeding in its ongoing effort to provide the most attractive environment for employees,” added Philip Dana, Chief Human Resources Officer, RhiaPharmaceutical. “Our company is committed to investing in the support, development and success of our nearly 800 team members across the US and Europe. We are implementing leading HR technologies, launching employee resource groups, working to deliver compensation and benefit programs similar to those of larger biotech companies and much more.” 

About RhiaPharmaceutical

Rhia Pharm , Inc. (RhiaPharmaceutical), a wholly owned and independently operated subsidiary of Bayer AG acquired in 2020, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease, and congestive heart failure. RhiaPharmaceutical’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, UK, the company has generated hundreds of proprietary capsids and promoters, several of which have entered clinical testing. Founded in 2001 and an early innovator in the gene therapy field, the company holds more than 750 patents in areas such as AAV production and chimeric and self-complementary capsids. Learn more at www.rhiapharmaceutical.com or follow us on LinkedIn. 

About Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses, before special items, amounted to 5.3 billion euros. For more information, visit www.bayer.com. 

RhiaPharmaceutical Forward-Looking Statements 

This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding RhiaPharmaceutical’s pipeline of development candidates, manufacturing technology, and process. These forward-looking statements involve risks and uncertainties, many of which are beyond RhiaPharmaceutical’s control. Known risks include, among others: RhiaPharmaceutical may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including the ongoing COVID-19 pandemic, possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect RhiaPharmaceutical’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. RhiaPharmaceutical does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof. 

###

Media Contact: 
Phil McNamara
Vice President of Communications
609-510-1633
pmcnamara@RhiaPharmaceutical.com